LONG-TERM CLINICAL RESULTS FOR SOFT-TISSUE AND BONE SARCOMAS

Abstract

Background: Although sarcomas are uncommon, they are extremely tough to identify and treat, necessitating a
multidisciplinary approach from pathologists, surgeons, radiologists, and/or oncologists.
Objectives: This clinical study examined the management and clinical outcomes of many sarcomas, such as
osteosarcoma, chondrosarcoma, soft tissue sarcomas, and Ewing sarcomas.
Methods: At baseline, all research participants' demographic and tumor features were documented for 225
sarcomas. Tumor necrosis following surgery was assessed histopathologically for osteosarcoma and Ewing
sarcoma. The gathered information was examined, and conclusions were drawn.
Results: The results showed that the mean event-free survival and disease survival for osteosarcoma were 46 (41–
53) months and 53 (47–57) months, respectively, following a 2-year follow-up. Regarding Ewing sarcoma, the
metastatic group's disease-free and overall survival rates at follow-up were 33.3% (n = 5) and 66.6% (n = 10)
respectively. At two recall intervals, the overall survival rate for instances of soft-tissue sarcoma was 63.26%
(n=31) and 38.77% (n=19) patients, respectively.
Conclusion: In light of its limitations, the current study came to the conclusion that chemotherapy produces
superior clinical outcomes for sarcomas, such as soft-tissue sarcoma, osteosarcoma, chondrosarcoma, and Ewing
sarcoma.